A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2002
11/07/2002	WO2002088366A1 Von willebrand factor (vwf)-cleaving enzyme
11/07/2002	WO2002088343A2 RECOMBINANT EXPRESSION OF hHBV REVERSE TRANSCRIPTASE (RT)
11/07/2002	WO2002088323A2 Gene delivery compounds
11/07/2002	WO2002088322A2 Cell adhesion and extracellular matrix proteins
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088314A2 Ovary-specific genes and proteins
11/07/2002	WO2002088180A2 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
11/07/2002	WO2002088167A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	WO2002088159A1 Pharmaceutically active uridine esters
11/07/2002	WO2002088097A1 Triazole-derived kinase inhibitors and uses thereof
11/07/2002	WO2002088093A1 Benzimidazoles that are useful in treating sexual dysfunction
11/07/2002	WO2002088090A2 Pyrazole derived kinase inhibitors
11/07/2002	WO2002088080A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088079A2 Dual inhibitors of pde 7 and pde 4
11/07/2002	WO2002088073A1 Anthranilic acid amides, method for the production thereof, their use as antiarrhythmia agents, and pharmaceutical preparations thereof
11/07/2002	WO2002087621A1 Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
11/07/2002	WO2002087620A1 Chondrogenesis promoters
11/07/2002	WO2002087607A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
11/07/2002	WO2002087596A2 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases
11/07/2002	WO2002087590A1 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
11/07/2002	WO2002087589A1 Medicine for inhibiting drug elimination pump
11/07/2002	WO2002087586A1 Sustained release drug delivery system containing codrugs
11/07/2002	WO2002087585A1 Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
11/07/2002	WO2002087584A1 Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
11/07/2002	WO2002087583A2 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
11/07/2002	WO2002087581A1 Novel salt and crystalline forms of (2r)-anti-5-{3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy}quinoline
11/07/2002	WO2002087576A1 The treatment of scarring and related conditions using ppar-gamma activators
11/07/2002	WO2002087575A1 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents
11/07/2002	WO2002087574A2 Use of pyridoindolone derivatives for preparing anticancer medicines
11/07/2002	WO2002087570A1 Composition comprising antifungal agents for treating vulvovaginitis and vaginosis
11/07/2002	WO2002087565A1 Inhibition of pigmentation by inhibition of fatty acid synthase
11/07/2002	WO2002087563A2 Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
11/07/2002	WO2002087561A1 Method of treating age-related vision impairment
11/07/2002	WO2002087556A2 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
11/07/2002	WO2002087554A2 Ef-tu binding agent as antibacterial agent
11/07/2002	WO2002087513A2 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
11/07/2002	WO2002087510A2 Subcellular targeting of therapeutic proteins
11/07/2002	WO2002087508A2 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
11/07/2002	WO2002087503A2 Compositions and methods for treating colorectal polyps and cancer
11/07/2002	WO2002087424A2 Treatment and diagnosis of macrophage mediated disease
11/07/2002	WO2002087411A2 Composite scaffolds and methods using same for generating complex tissue grafts
11/07/2002	WO2002087335A1 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
11/07/2002	WO2002056872A3 Antiproliferative colchicine compositions and uses thereof
11/07/2002	WO2002040649A8 Slo2 and slo4, novel potassium channel proteins from human brain
11/07/2002	WO2002040030A8 Combination therapy for lowering and controlling intraocular pressure
11/07/2002	WO2002028897A3 Human g-protein coupled receptor and uses thereof
11/07/2002	WO2002009667A3 Dispersions for formulating slightly or poorly soluble active ingredients
11/07/2002	WO2001091765A3 Compositions for treating eye discomfort containing herbals and/or nutritional supplements and/or minerals and/or vitamins
11/07/2002	WO2001086002A9 Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
11/07/2002	WO2001042784A9 Methods for screening compounds active on neurons
11/07/2002	WO2001027079A9 Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
11/07/2002	WO2001026676A9 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
11/07/2002	WO2001020034A9 Methods and compositions for the screening of cell cycle modulators
11/07/2002	WO2001015745A9 Method and formula for tumor remission and suppression of cancer
11/07/2002	WO2001010454A9 Pharmaceutical composition comprising peg-asparaginase for the treatment of hiv infection
11/07/2002	US20020165608 Local drug delivery devices and methods for maintaining the drug coatings thereon
11/07/2002	US20020165386 C-junction-n-terminal kinase (JNK); microbiocides; treating neurodegenerative diseases
11/07/2002	US20020165380 A nucleic acid probe consisting a nucleic acid molecule of at least 15 nucleotides which is complementary to the antisense sequence of a unique fragment of the sequence of a nucleic acid molecule encoding a mammalian fb41 receptor
11/07/2002	US20020165377 ADAM polynucleotides, polypeptides, and antibodies
11/07/2002	US20020165361 Antibody for use in the diagnosis and treatment of cell proliferation disorders
11/07/2002	US20020165347 Polypeptide for use in the diagnosis, prevention and treatment of arteriosclerosis and vascular restenosis
11/07/2002	US20020165343 Growth hormone secretagogues
11/07/2002	US20020165282 PPAR agonists
11/07/2002	US20020165275 Trisubstituted carbocyclic cyclophilin binding compounds and their use
11/07/2002	US20020165268 Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease
11/07/2002	US20020165265 Microtubule disrupter such as paclitaxel, and a polymeric carrier that is NOT a capsule; embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions
11/07/2002	US20020165258 For tumors that have initially been unresponsive to taxane therapy and developed drug resistance
11/07/2002	US20020165255 Prostaglandin agonists such as (3-(methanesulfonylamino-methyl)-phenoxy)-acetic acid methyl ester for preventing/ restoring bone mass loss
11/07/2002	US20020165249 Nasal delivery of apomorphine
11/07/2002	US20020165240 Method of treating proliferative diseases using Eg5 inhibitors
11/07/2002	US20020165237 Treatment of the insulin resistance syndrome
11/07/2002	US20020165233 Quinoxaline containing medicaments for post exposure prophylaxis of an HIV infection
11/07/2002	US20020165227 Gramnegative bacteria
11/07/2002	US20020165218 Mixture of kinase inhibitor and anticancer agents
11/07/2002	US20020165217 Combination treatment for anxiety and depression
11/07/2002	US20020165207 Mixture of nerve growth factor, aldose reductase inhibitor and oxidation resistance
11/07/2002	US20020165201 Cyanoguanidine prodrugs
11/07/2002	US20020165197 Administering adenosine receptor ligand
11/07/2002	US20020165193 Compositions and methods of treating tumors
11/07/2002	US20020165186 Compounds that affect CD83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/07/2002	US20020165166 Treating thrombosis by administering a CD154 inhibitor, such as a metalloproteinase inhibitor
11/07/2002	US20020165154 Lipoprotein-regulating medicaments
11/07/2002	US20020165131 Histidine-rich glycoprotein
11/07/2002	US20020165123 CXCR4 agonist treatment of hemapoietic cells
11/07/2002	US20020165120 Mixture of eletriptan and glycoprotein inhibitor; headache therapy
11/07/2002	US20020164789 Suppressing glial cell activation in central nervous system; obtain mammal with brain disorder, administer modulator of nervous system activity, evaluate for adjusstment in brain disorder
11/07/2002	US20020164767 DNA encoding the human serine protease C-E
11/07/2002	US20020164748 Enzymatic polypeptide for use in the treatment of inflammation, autoimmune and tissue rejection disorders
11/07/2002	US20020164734 Human pelota homolog
11/07/2002	US20020164722 Generating preferential polymerase in sample; obtain nucleotide sequences, incubate in reaction mixture, translate nucleotide sequences, recover polypeptide
11/07/2002	US20020164707 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of cancer, arthrits, pain, diabetes, migraine and inflammation, hypercalcemia, obesity, hypertension, and bone defects
11/07/2002	US20020164386 Topical applying glucosamine containing cream
11/07/2002	US20020164378 Use of bioactive fraction from cow urine distillate ('Go-mutra') as a bio-enhancer of anti-infective, anti-cancer agents and nutrients
11/07/2002	US20020164377 Mixture of retinoic acid and paclitaxel; polymeric carrier
11/07/2002	US20020164319 Medical use of matrix metalloproteinase inhibitors for inhibiting tissue contraction
11/07/2002	US20020164312 Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
11/07/2002	US20020162769 Antihistamine/decongestant regimens for treating rhinitis
11/07/2002	DE10121252A1 Behandlung der Akne Treatment of acne
11/07/2002	CA2665516A1 Drug efflux pump inhibitor
11/07/2002	CA2594883A1 Pharmaceutically active uridine esters

1 ... 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 ... 1151